This page is an archive. Its content may no longer be accurate and was last updated on the original publication date. It is intended for reference and as a historical record only. For hep C questions, call Help4Hep BC at 1-888-411-7578.
Hepatitis C virus (HCV) antiviral therapy in liver transplant candidates with decompensated cirrhosis may result in long-term improvement in liver function, giving as many as 1 in 3 patients the possibility of being taken off the transplant list, according to a study published in Liver International.
Many people infected with HCV who have decompensated cirrhosis are on the waiting list for liver transplantation. A previous study by the European Liver and Intestine Transplant Association, however, showed that treatment with second-generation direct-acting antivirals (DAAs) resulted in nearly 25% of patients being taken off the transplant list because of clinical improvement.